Combination of ligand- and structure-based methods in virtual screening

Wilson, 2011, Integrating structure-based and ligand-based approaches for computational drug design, Future Med. Chem., 3, 735, 10.4155/fmc.11.18 Sperandio, 2008, Combining ligand- and structure-based methods in drug design projects, Curr. Comput. Aided Drug Des., 4, 250, 10.2174/157340908785747447 Verma, 2010, 3D-QSAR in drug design – a review, Curr. Top. Med. Chem., 10, 95, 10.2174/156802610790232260 Hu, 2012, Performance evaluation of 2D fingerprint and 3D shape similarity methods in virtual screening, J. Chem. Inf. Model., 52, 1103, 10.1021/ci300030u Leach, 2010, Three-dimensional pharmacophore methods in drug discovery, J. Med. Chem., 53, 539, 10.1021/jm900817u Schuster, 2010, 3D pharmacophores as tools for activity profiling, Drug Discov. Today: Technol., 7, e205, 10.1016/j.ddtec.2010.11.006 Hessler, 2010, The scaffold hopping potential of pharmacophores, Drug Discov. Today: Technol., 7, e263, 10.1016/j.ddtec.2010.09.001 Hein, 2010, Docking compared to 3D-pharmacophores: the scoring function challenge, Drug Discov. Today: Technol., 7, e229, 10.1016/j.ddtec.2010.12.003 Meng, 2011, Molecular docking: a powerful approach for structure-based drug discovery, Curr. Comput. Aided Drug Des., 7, 146, 10.2174/157340911795677602 Ivetac, 2011, Molecular recognition in the case of flexible targets, Curr. Pharm. Des., 17, 1663, 10.2174/138161211796355056 Löwer, 2011, Structure-based pharmacophores for virtual screening, Mol. Inf., 30, 398, 10.1002/minf.201100007 Sanders, 2012, From the protein's perspective: the benefits and challenges of protein structure-based pharmacophore modeling, MedChemComm, 3, 28, 10.1039/C1MD00210D Sutter, 2011, New features that improve the pharmacophore tools from accelrys, Curr. Comput. Aided Drug Des., 7, 173, 10.2174/157340911796504305 Cross, 2010, Grid-derived structure-based 3D pharmacophores and their performance compared to docking, Drug Discov. Today: Technol., 7, e213, 10.1016/j.ddtec.2010.09.002 Khan, 2010, Identification of potent urease inhibitors via ligand- and structure-based virtual screening and in vitro assays, J. Mol. Graphics Modell., 28, 792, 10.1016/j.jmgm.2010.02.004 Weidlich, 2010, Inhibitors of human tyrosyl-DNA phosphodiesterase (hTdp1) developed by virtual screening using ligand-based pharmacophores, Bioorg. Med. Chem., 18, 182, 10.1016/j.bmc.2009.11.008 Banoglu, 2012, Identification of novel benzimidazole derivatives as inhibitors of leukotriene biosynthesis by virtual screening targeting 5-lipoxygenase-activating protein (FLAP), Bioorg. Med. Chem., 20, 3728, 10.1016/j.bmc.2012.04.048 Drwal, 2011, Exploring DNA topoisomerase I ligand space in search of novel anticancer agents, PLoS ONE, 6, e25150, 10.1371/journal.pone.0025150 Smith, 2012, Novel indoleamine 2,3-dioxygenase-1 inhibitors from a multistep in silico screen, Bioorg. Med. Chem., 20, 1354, 10.1016/j.bmc.2011.10.068 Svensson, 2012, Virtual screening data fusion using both structure- and ligand-based methods, J. Chem. Inf. Model., 52, 225, 10.1021/ci2004835 Swann, 2011, A unified, probabilistic framework for structure- and ligand-based virtual screening, J. Med. Chem., 54, 1223, 10.1021/jm1013677 Tan, 2008, Integrating structure- and ligand-based virtual screening: comparison of individual, parallel, and fused molecular docking and similarity search calculations on multiple targets, ChemMedChem, 3, 1566, 10.1002/cmdc.200800129 Salam, 2009, Novel method for generating structure-based pharmacophores using energetic analysis, J. Chem. Inf. Model., 49, 2356, 10.1021/ci900212v Wolber, 2005, LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters, J. Chem. Inf. Model., 45, 160, 10.1021/ci049885e Meslamani, 2012, Protein–ligand-based pharmacophores: generation and utility assessment in computational ligand profiling, J. Chem. Inf. Model., 52, 943, 10.1021/ci300083r Chen, 2010, Multiple pharmacophore models combined with molecular docking: a reliable way for efficiently identifying novel PDE4 inhibitors with high structural diversity, J. Chem. Inf. Model., 50, 615, 10.1021/ci9004173 Postigo, 2010, Discovery of new inhibitors of Schistosoma mansoni PNP by pharmacophore-based virtual screening, J. Chem. Inf. Model., 50, 1693, 10.1021/ci100128k Planesas, 2011, Improving VEGFR-2 docking-based screening by pharmacophore postfiltering and similarity search postprocessing, J. Chem. Inf. Model., 51, 777, 10.1021/ci1002763 Spitzer, 2010, One concept, three implementations of 3D pharmacophore-based virtual screening: distinct coverage of chemical search space, J. Chem. Inf. Model., 50, 1241, 10.1021/ci100136b Chen, 2012, Discovery of a novel acetylcholinesterase inhibitor by structure-based virtual screening techniques, Bioorg. Med. Chem. Lett., 22, 3181, 10.1016/j.bmcl.2012.03.046 Yoo, 2011, Homology modeling, docking and structure-based pharmacophore of inhibitors of DNA methyltransferase, J. Comput. Aided Mol. Des., 25, 555, 10.1007/s10822-011-9441-1 Pinto, 2011, Rational design of new class of BH3-mimetics as inhibitors of the Bcl-xL protein, J. Chem. Inf. Model., 51, 1249, 10.1021/ci100501d Tanrikulu, 2008, Pseudoreceptor models in drug design: bridging ligand- and receptor-based virtual screening, Nat. Rev. Drug Discov., 7, 667, 10.1038/nrd2615 Holliday, 2011, Multiple search methods for similarity-based virtual screening: analysis of search overlap and precision, J. Chem. Inf., 3, 1 Scior, 2012, Recognizing pitfalls in virtual screening: a critical review, J. Chem. Inf. Model., 52, 867, 10.1021/ci200528d Huang, 2006, Benchmarking sets for molecular docking, J. Med. Chem., 49, 6789, 10.1021/jm0608356 Schneider, 2010, Virtual screening: an endless staircase?, Nat. Rev. Drug Discov., 9, 273, 10.1038/nrd3139